United Capital Financial Advisors’s Indaptus Therapeutics INDP Stock Holding History

United Capital Financial Advisors’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-536	Closed	-$60K	–	1158
2022 Q1	$60K	Hold	536	–	–	﹤0.01%	1138
2021 Q4	$86K	Buy	+536	New	+$99.6K	﹤0.01%	1179
2020 Q4	–	Sell	-12	Closed	-$7K	–	1212
2020 Q3	$7K	Buy	+12	New	+$8.82K	﹤0.01%	1150

Other funds holding INDP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IHL

Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

VCM

Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

United Capital Financial Advisors's INDP Position: Q2 2022 in Review

United Capital Financial Advisors sold out of Indaptus Therapeutics (INDP) in Q2 2022, closing a stake of 536 shares — an estimated $60K sold.

United Capital Financial Advisors first reported a position in INDP in Q3 2020 and held it in 3 quarters. The position peaked at $86K in Q4 2021. 15 funds tracked by Wall St. Rank hold INDP as of Q2 2022.

United Capital Financial Advisors reported no remaining Indaptus Therapeutics position as of Q2 2022 after selling out during the quarter.
United Capital Financial Advisors sold 536 Indaptus Therapeutics shares in Q2 2022, an estimated $60K.
United Capital Financial Advisors first reported a position in Indaptus Therapeutics in Q3 2020 and held it in 3 quarters.
United Capital Financial Advisors's Indaptus Therapeutics position peaked at $86K in Q4 2021.
15 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2022.

Based on United Capital Financial Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.